Prosight Management, LP
- SEC CIK
- 0001617201
Holdings, Q2 2026
Positions as of Jun 30, 2026, filed Aug 14, 2026.SEC
- Positions
- 36
- −10 vs. Q1 2026
- Total value
- $580.35M
- −$29.47M (−4.8%) vs. Q1 2026
Compare with Q1 2026: new, added, reduced and sold out
Positions
Long positions only. Changes compare share counts with Q1 2026.
| Security | Class | Shares | Value | % of portfolio | Change in shares | Action | History |
|---|---|---|---|---|---|---|---|
| LKFTLAKEFRONT BIOTHERAPEUTICS NV | SPON ADR | 2,043,344 | $61.26M | 10.56% | +493,344+31.8% | Added | View |
| JANXJANUX THERAPEUTICS INC | COM | 3,804,481 | $58.44M | 10.07% | +254,481+7.2% | Added | View |
| NKTRNEKTAR THERAPEUTICS | COM NEW | 810,000 | $56.55M | 9.74% | +75,000+10.2% | Added | View |
| BSXBOSTON SCIENTIFIC CORP COM | Stock | 1,270,273 | $54.22M | 9.34% | +474,726+59.7% | Added | View |
| STTKSHATTUCK LABS INC | COM | 5,957,877 | $41.35M | 7.12% | +953,438+19.1% | Added | View |
| INSMINSMED INC | COM PAR $.01 | 375,609 | $40.05M | 6.90% | +375,609 | New | View |
| ALNYALNYLAM PHARMACEUTICALS INC | COM | 98,080 | $29.53M | 5.09% | +22,080+29.1% | Added | View |
| SNDXSYNDAX PHARMACEUTICALS INC | COM | 1,200,000 | $26.23M | 4.52% | +430,000+55.8% | Added | View |
| KURAKURA ONCOLOGY INC | COM | 2,021,964 | $22.18M | 3.82% | −1,334,736−39.8% | Reduced | View |
| ALKSALKERMES PLC | SHS | 394,389 | $20.66M | 3.56% | −119,243−23.2% | Reduced | View |
| IRTCIRHYTHM TECHNOLOGIES INC | COM | 165,500 | $19.69M | 3.39% | +155,500+1,555.0% | Added | View |
| VEEVVEEVA SYS INC CL A COM | Stock | 106,200 | $18.85M | 3.25% | +19,720+22.8% | Added | View |
| ZYMEZYMEWORKS INC | COM | 674,434 | $17.63M | 3.04% | +135,385+25.1% | Added | View |
| ABVXABIVAX SA | SPONSORED ADS | 107,394 | $14.31M | 2.47% | +2,394+2.3% | Added | View |
| CRINETICS PHARMACEUTICALS IN22663K107 | COM | 374,666 | $14.02M | 2.42% | +24,666+7.0% | Added | – |
| MLYSMINERALYS THERAPEUTICS INC | COM | 449,795 | $12.14M | 2.09% | +449,795 | New | View |
| ADCTADC THERAPEUTICS SA | SHS | 7,824,749 | $8.37M | 1.44% | −475,251−5.7% | Reduced | View |
| ICUIICU MED INC | COM | 51,000 | $7.48M | 1.29% | +23,550+85.8% | Added | View |
| ISRGINTUITIVE SURGICAL INC | COM NEW | 17,000 | $6.76M | 1.16% | +13,000+325.0% | Added | View |
| CRBPCORBUS PHARMACEUTICALS HLDGS | COM NEW | 650,000 | $6.1M | 1.05% | −47,108−6.8% | Reduced | View |
| PRCTPROCEPT BIOROBOTICS CORP | COM | 268,269 | $6.06M | 1.04% | −1,676,731−86.2% | Reduced | View |
| WGSGENEDX HOLDINGS CORP | COM CL A | 85,500 | $5.87M | 1.01% | −437,963−83.7% | Reduced | View |
| OPCHOPTION CARE HEALTH INC | COM NEW | 270,716 | $5.68M | 0.98% | +270,716 | New | View |
| OKURONKURE THERAPEUTICS INC | COM CL A | 978,992 | $4.46M | 0.77% | −1,175,389−54.6% | Reduced | View |
| EBSEMERGENT BIOSOLUTIONS INC | COM | 459,952 | $3.85M | 0.66% | −179,166−28.0% | Reduced | View |
| PFEPFIZER INC COM | Stock | 135,366 | $3.26M | 0.56% | +135,366 | New | View |
| KIDSORTHOPEDIATRICS CORP | COM | 157,500 | $3.01M | 0.52% | −144,899−47.9% | Reduced | View |
| RCKTROCKET PHARMACEUTICALS INC | COM | 700,000 | $2.39M | 0.41% | +16,144+2.4% | Added | View |
| ANTXAN2 THERAPEUTICS INC | COM | 474,638 | $2.3M | 0.40% | −41,116−8.0% | Reduced | View |
| PLRXPLIANT THERAPEUTICS INC | COM | 1,370,233 | $1.56M | 0.27% | −297,367−17.8% | Reduced | View |
| TECXTECTONIC THERAPEUTIC INC | COM | 39,731 | $1.37M | 0.24% | −40,141−50.3% | Reduced | View |
| MGTXMEIRAGTX HLDGS PLC | COM | 90,000 | $1.22M | 0.21% | −2,539,971−96.6% | Reduced | View |
| EFOREVERFORTH INC | COM | 67,500 | $1.21M | 0.21% | +67,500 | New | View |
| RNTXREIN THERAPEUTICS INC | COM NEW | 1,100,000 | $1.14M | 0.20% | +688,400+167.2% | Added | View |
| COYACOYA THERAPEUTICS INC | COMMON STOCK | 170,000 | $994.5K | 0.17% | −250,360−59.6% | Reduced | View |
| IMRXIMMUNEERING CORP | CLASS A COM | 36,861 | $183.94K | 0.03% | −86,548−70.1% | Reduced | View |
Sold out since Q1 2026 (15)
Positions held at the end of Q1 2026 that are no longer in this filing.
| Security | Class | Shares, Q1 2026 | Value, Q1 2026 | % of portfolio, Q1 2026 |
|---|---|---|---|---|
| CONCONCENTRA GROUP HOLDINGS PAR | COMMON STOCK | 505,822 | $10.85M | 1.78% |
| TERNS PHARMACEUTICALS INC880881107 | COM | 202,300 | $10.67M | 1.75% |
| PHRPHREESIA INC | COM | 1,100,000 | $9.22M | 1.51% |
| SDGRSCHRODINGER INC | COM | 510,578 | $5.8M | 0.95% |
| ROIVROIVANT SCIENCES LTD | SHS | 180,000 | $4.99M | 0.82% |
| IMVTIMMUNOVANT INC | COM | 175,825 | $4.37M | 0.72% |
| UPBUPSTREAM BIO INC | COM | 241,123 | $2.17M | 0.36% |
| OMEROMEROS CORP | COM | 174,800 | $1.85M | 0.30% |
| ACETADICET BIO INC | COM NEW | 250,244 | $1.7M | 0.28% |
| RGNXREGENXBIO INC | COM | 200,000 | $1.68M | 0.27% |
| VKTXVIKING THERAPEUTICS INC | COM | 45,000 | $1.46M | 0.24% |
| TBITRUEBLUE INC | COM | 249,107 | $974.01K | 0.16% |
| PVLAPALVELLA THERAPEUTICS INC NE | COM | 5,000 | $623.25K | 0.10% |
| NVCRNOVOCURE LTD | ORD SHS | 50,400 | $549.36K | 0.09% |
| TMDXTRANSMEDICS GROUP INC | COM | 5,000 | $497.05K | 0.08% |
13F filings by quarter
| Quarter | Filed | Positions | Total value | Changes | Filing |
|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 36 | $580.35M | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 46 | $609.82M | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 13, 2026 | 38 | $483.93M | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 41 | $416.49M | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 39 | $410.06M | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 38 | $304.34M | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 35 | $356.97M | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 41 | $394.35M | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 46 | $334.57M | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 44 | $359.45M | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 34 | $249.08M | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 41 | $315.54M | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023Amended | 35 | $341.58M | vs. Q1 2023 | SEC |
| Q1 2023 | May 12, 2023 | 39 | $208.77M | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 37 | $178.84M | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 36 | $181.94M | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 12, 2022 | 23 | $123.46M | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 30 | $142.07M | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 32 | $150.21M | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 12, 2021 | 40 | $170.95M | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 13, 2021 | 44 | $157.9M | vs. Q1 2021 | SEC |
| Q1 2021 | May 14, 2021 | 37 | $122.12M | – | SEC |